ME/CFS Science @mecfsscience.org · 17/09/20268 ) It's interesting that most outcomes favour the Bezisterim group. Although there were reportedly few side-effects, it could be that some broke the blinding so that patients knew that they were on the drug. That's a potential limitation. 180
ME/CFS Science @mecfsscience.org · 17/09/20269) The stock of the company dropped by ca. 20% after the announcement, suggesting that investors were not convinced by the subgroup analysis. This is similar to what happened with the phase 2 trial of Bezisterim for Parkinson's Disease in August. 280
ME/CFS Science @mecfsscience.org · 17/09/202610) The company also has a problematic past with a failed phase 3 trial for Alzheimer, litigations and a controversial (former) CEO. More about that here: s4me.info/threads/a-... Link to the announcement: investors.bioviephar...s4me.infoClosed - A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of Bezisterim (NE3107) in Adults With Long COVID (ADDRESS-LC) | Page 3 | Science for MEhttps://www.investing.com/news/stock-market-news/why-is-biovie-stock-sliding-today-93CH-4901757 “While the headline result was a miss, the data picture was... 1150
calltobase.bsky.social @calltobase.bsky.social · 17/09/2026To be fair a lot of trading is automated and responds directly to headlines these days. So it might have just been the “failed primary endpoint” headline leading to that effect 010
